Press Releases

Emplicures board member Johan Wieslander acquires additional warrants of series TO1 and exercises the warrants for subscription of shares for app. SEK 3.1 million

Johan Wieslander, who is a board member of Emplicure AB (publ) ("Emplicure" or the "Company"), has acquired an additional 1,500,000 warrants of series TO1, in addition to the warrants previously held by him that have already been exercised for subscription of shares in the Company. Johan Wieslander  has exercised the the additional 1,500,000 warrants for subscription of 1,500,000 shares in the Company, meaning that the Company receives approximately SEK 3.1 million.

Summarized terms for warrants of series TO1:

Last day of exercise of TO1 for subscription of shares: May 13, 2022.

Subscription price: SEK 2.09 per share.

Volume: 9,600,000 warrants of series TO1. If all warrants of series TO1 are exercised, the number of shares in the Company will increase with 9,600,00 shares, and the Company will receive approximately SEK 20.1 million before issuing costs.

Last day for trading with warrants of series TO1: May 11, 2022.

Advisors
Mangold Fondkommission AB is the financial advisor and issuing agent and Advokatfirman Lindahl KB is the legal advisor to Emplicure in connection with the exercise of the warrants.

For more information, please contact:

Torbjörn W. Larsson
CEO
Phone: +46 (0)70 747 65 99
Email: torbjorn.walkerlarsson@emplicure.com

Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: erik.magnusson@emplicure.com

Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with white tobacco-free nicotine pouches as the first product. Read more at www.emplicure.com

2023-06-05
Regulatory

The board of directors of Emplicure AB (publ) ("Emplicure" or the "Company") recommends the shareholders of Emplicure not to accept the mandatory takeover offer of SEK 0.50 per share made by TomEQT Private AB ("TomEQT Private") on May 29, 2023.

2023-05-29
Regulatory

TomEQT Private AB ("TomEQT Private") has today announced a mandatory takeover offer in cash for the shares in Emplicure AB (publ) ("Emplicure" or the "Company") at a price of SEK 0.50 per share (the "Offer"). The Offer is made in accordance with the rules regarding mandatory takeover offers since TomEQT Private's shareholding in Emplicure, following the directed issue of shares resolved by the board of directors of Emplicure on 24 May 2023, now amounts to approximately 50.6 percent of the total number of shares and votes in Emplicure.

2023-05-24
Regulatory

The board of directors of Emplicure AB (publ) ("Emplicure" or the "Company") has today, as authorised by the general meeting on 2 May 2023, resolved on a directed issue of 50,000,000 new shares through which the Company receives 25,000,000 SEK before issue costs (the "Directed Issue"). The right to subscribe for shares in the Directed Issue shall, with deviation from the shareholders pre-emption rights, belong to TomEQT Private AB (the "Investor"). The subscription price in the Directed Issue is 0.50 SEK per share and has been determined after negotiations with the Investor. The reason for the deviation from the shareholders' pre-emption rights is that the board of directors, in an overall assessment and after careful consideration, considers that a directed issue to the Investor is the preferred alternative to meet the Company's capital needs and that it is objectively in the interest of both the Company and its shareholders to carry out the Directed Issue. The board of directors has carefully considered the possibility of carrying out a rights issue to raise the required capital but deemed that it would be more time-consuming and entail significantly higher costs and an increased market risk exposure. Through the Directed Issue, the Investor will reach a shareholding of approximately 50.6 percent of the outstanding shares and votes in the Company entailing that the mandatory bid threshold will be exceeded. The Investor has notified the board of directors that the Investor intends to fulfil its mandatory bid obligation and make a public takeover offer regarding the remaining shares in the Company.

2023-05-23
Regulatory

The 2022 Annual report of Emplicure AB (publ) is now available on the Company's website.

2023-05-11
Regulatory

The shareholders in Emplicure AB (publ) reg. no. 556967-7189 (the "Company") are hereby given notice that the Annual General Meeting will be held on Tuesday 13 June 2023, at 2.00 p.m. at the law firm Lindahl's premises, Vaksalagatan 10, Uppsala, Sweden. Registration starts at 1.45 p.m. and will stop when the meeting starts.

2023-05-09
Regulatory
2023-05-02
Regulatory

The extra general meeting in Emplicure AB (publ), corp. reg. no 556967-7189 (the "Company") was held on 2 May 2023 in Uppsala whereby the shareholders primarily resolved on the following matters.

2023-04-21

Amplicon är glada över att kunna presentera Småå, ett helt nytt koncept inom vita, tobaksfria nikotinpåsar som förhöjer upplevelsen för konsumenten. Innehållet i Småås påsar utformas med patenterad biokeramisk teknik som gör det möjligt att erbjuda riktigt små påsar med betydligt längre smak- och nikotinupplevelse.

1
2
...
9
>>

Do you want to know more?